W
Weihong Wang
Publications - 4
Citations - 656
Weihong Wang is an academic researcher. The author has contributed to research in topics: Lopinavir & Ritonavir. The author has an hindex of 3, co-authored 4 publications receiving 599 citations.
Papers
More filters
Journal ArticleDOI
Clinical findings in 111 cases of influenza A (H7N9) virus infection
Hainv Gao,Hongzhou Lu,Bin Cao,Bin Du,Hong Shang,Jianhe Gan,Shuihua Lu,Yida Yang,Qiang Fang,Yinzhong Shen,Xiuming Xi,Qin Gu,Xian-Mei Zhou,Hong-Ping Qu,Zheng Yan,Fang-Ming Li,Wei Zhao,Zhancheng Gao,Guang-Fa Wang,Lingxiang Ruan,Weihong Wang,Jun Ye,Hui-Fang Cao,Xingwang Li,Wenhong Zhang,Xu-Chen Fang,Jian He,Weifeng Liang,Juan Xie,Mei Zeng,Xianzheng Wu,Jun Li,Qi Xia,Zhao-Chen Jin,Qi Chen,Chao Tang,Zhiyong Zhang,Bao-Min Hou,Zhi-Xian Feng,Jifang Sheng,Nanshan Zhong,Lanjuan Li +41 more
TL;DR: The presence of a coexisting medical condition was the only independent risk factor for the acute respiratory distress syndrome (ARDS) during the evaluation period, and the novel H7N9 virus caused severe illness, including pneumonia and ARDS, with high rates of ICU admission and death.
Journal ArticleDOI
Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study.
Yan Zhang,Pengfei Zou,Hai-nv Gao,Meifang Yang,Ping Yi,Jianhe Gan,Yinzhong Shen,Weihong Wang,Wenhong Zhang,Jun Li,Peng Liu,Lanjuan Li +11 more
TL;DR: The study found that NLR was independently associated with fatality, and is potentially a predictive prognostic biomarker in patients infected with the AIV-H7N9 influenza virus.
Journal ArticleDOI
Early antiviral therapy of abidor combined with lopinavir/ritonavir and re-combinant interferonα-2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study
Runan Wei,Nanhong Zheng,Xiangao Jiang,Chunlian Ma,Xiaowei Xu,Shourong Liu,Yongping Chen,Kaijin Xu,Hainv Gao,Jiansheng Zhu,Qiang Shu,Jifang Sheng,Xiaoqiang Zhang,Minghui Li,Yan Zhang,Mengjie Ma,Xuan Zhang,Shibo Li,Qiujing Wang,Lingjun Ying,Yongjun Zhang,Yunzhen Shi,Lingyan Fan,Wanjun Yu,Huaying Wang,Dandan Sun,Xiaodong Wang,Ji-Chan Shi,Yinghu Chen,Xin-Sheng Xie,Yunqing Chen,Weihong Wang,Zhaowei Tong,Lingling Tang,Mengfei Zhu,Lingjian Zhang,Lanjuan Li +36 more
TL;DR: The triple combination antiviral therapy of Abidor, Lopinavir/Litonavir and recombinant interferon α-2b showed shorter viral shedding time and hospitalization time compared with the dual combination antivirus therapy.
Journal ArticleDOI
Early antiviral therapy of abidol combined with lopinavir/ritonavir and recombinant interferon α-2b for patients with COVID-19 in Zhejiang: A multicenter prospective study
Runan Wei,N. Zheng,X. Jiang,C. Ma,Xiao Xu,S. Liu,Yongping Chen,Kaijin Xu,Hainv Gao,J. Zhu,Qiang Shu,Jifang Sheng,Xuan Zhang,M. Li,Yan Zhang,M. Ma,S. Li,Q. Wang,L. Ying,Y. Shi,Lingyan Fan,W. Yu,Hui Wang,D. Sun,X. Wang,Ji-Chan Shi,Xin-Sheng Xie,Weihong Wang,Zhaowei Tong,Lingling Tang,Mengfei Zhu,Lingjian Zhang,Lanjuan Li +32 more
TL;DR: The triple combination antiviral therapy of abidol, lopinavir/litonavir and rIFNα-2b shows shorter viral shedding time and shorter hospitalization time, compared with the dual combination antivirus therapy; and the earlier starting triple combination anti-viral therapy will result in better antiviral efficacy.